Bruker Advances Functional Proteomics 2.0 with timsOmni Mass Spectrometry

Novel workflows enable deeper characterization of proteoforms and PTMs for disease biology insights

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

Bruker Corporation announced new advancements to its timsOmni mass spectrometer that enable Functional Proteomics 2.0 workflows. The updates include enhanced software capabilities for confident proteoform characterization, eXd-enabled glycoproteomics, and AI-powered de novo peptide sequencing to support complex applications like metaproteomics and immunopeptidomics.

Why it matters

These innovations from Bruker aim to help researchers move beyond just cataloging proteins to gaining deeper insights into disease biology, drug discovery, and biotherapeutics development by enabling more comprehensive analysis of proteoforms, post-translational modifications, and peptide variants.

The details

The new timsOmni workflows leverage multi-stage, ultra-sensitive trapped eXd molecular fragmentation to enable deeper functional characterization of proteoforms and PTMs. Bruker's updated ProteoScape, OmniScape, and GlycoScape software now support database-independent PTM discovery, confident proteoform characterization, and eXd-enabled glycoproteomics. Additionally, the AI-enhanced de novo peptide sequencing in ProteoScape enables discovery of peptide variants across complex samples like metaproteomics and immunopeptidomics.

  • Bruker announced the new advancements on February 23, 2026.

The players

Bruker Corporation

A leading provider of high-performance scientific instruments and high-value analytical and diagnostic solutions that enable scientists to explore life and materials at molecular, cellular, and microscopic levels.

Yehia Mechref

Professor and Director of the Texas Tech University Center for Biotechnology & Genomics, who commented on the capabilities of the timsOmni mass spectrometer and new software features.

Bin Ma

Founder of Rapid Novor Inc., a company that collaborated with Bruker to enable AI-enhanced de novo peptide sequencing in the ProteoScape software.

Got photos? Submit your photos here. ›

What they’re saying

“The timsOmni gives scientists access to eXd-enabled fragmentation that can resolve complex PTMs and proteoforms with outstanding fidelity. The new software capabilities—especially eXd N-glycopeptide analysis and improved top-down workflows—support deeper understanding of disease biology and provide new avenues for target discovery and translational research.”

— Yehia Mechref, Professor and Director, Texas Tech University Center for Biotechnology & Genomics

“Researchers are increasingly studying biological systems where reference databases alone do not capture the true molecular diversity. Our collaboration with Bruker has enabled Novor.AI to take advantage of large, high-quality timsTOF datasets and combine them with our AI model to deliver the speed, confidence, and precision needed for next-generation de novo peptide sequencing applications.”

— Bin Ma, Founder, Rapid Novor Inc.

The takeaway

Bruker's advancements in its timsOmni mass spectrometry platform and supporting software aim to enable researchers to gain deeper insights into disease biology, drug discovery, and biotherapeutics development by providing more comprehensive analysis of proteoforms, post-translational modifications, and peptide variants beyond just cataloging proteins.